Kari L. Ring

2.0k total citations
74 papers, 1.3k citations indexed

About

Kari L. Ring is a scholar working on Pathology and Forensic Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, Kari L. Ring has authored 74 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 25 papers in Oncology and 23 papers in Reproductive Medicine. Recurrent topics in Kari L. Ring's work include Genetic factors in colorectal cancer (25 papers), Ovarian cancer diagnosis and treatment (23 papers) and Endometrial and Cervical Cancer Treatments (19 papers). Kari L. Ring is often cited by papers focused on Genetic factors in colorectal cancer (25 papers), Ovarian cancer diagnosis and treatment (23 papers) and Endometrial and Cervical Cancer Treatments (19 papers). Kari L. Ring collaborates with scholars based in United States, Italy and Canada. Kari L. Ring's co-authors include Anne M. Mills, Susan C. Modesitt, Emily A. Sloan, Mark F. Munsell, Russell R. Broaddus, Karen H. Lu, Molly S. Daniels, Amanda Bruegl, Pamela T. Soliman and Michael Frumovitz and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and American Journal of Epidemiology.

In The Last Decade

Kari L. Ring

68 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kari L. Ring United States 20 500 467 406 377 302 74 1.3k
Bojana Djordjevic Canada 25 314 0.6× 808 1.7× 672 1.7× 412 1.1× 392 1.3× 57 1.9k
Mervi Aavikko Finland 15 230 0.5× 585 1.3× 501 1.2× 203 0.5× 186 0.6× 27 1.3k
David T. Bollag France 7 646 1.3× 205 0.4× 1.1k 2.7× 276 0.7× 135 0.4× 11 1.4k
Yaser Hussein United States 18 208 0.4× 665 1.4× 508 1.3× 214 0.6× 317 1.0× 27 1.1k
M.L. Carcangiu Italy 15 390 0.8× 326 0.7× 334 0.8× 147 0.4× 439 1.5× 31 1.1k
Peter Lim Canada 16 316 0.6× 1.1k 2.3× 806 2.0× 108 0.3× 138 0.5× 32 1.5k
Barbara M. Buttin United States 16 234 0.5× 250 0.5× 272 0.7× 264 0.7× 245 0.8× 28 858
Michael K. Cheung United States 17 309 0.6× 1.1k 2.4× 1.1k 2.6× 155 0.4× 107 0.4× 34 1.7k
Antonio De Leo Italy 17 228 0.5× 197 0.4× 170 0.4× 130 0.3× 155 0.5× 101 869
Vincent Castonguay Canada 11 563 1.1× 415 0.9× 174 0.4× 91 0.2× 106 0.4× 43 1.0k

Countries citing papers authored by Kari L. Ring

Since Specialization
Citations

This map shows the geographic impact of Kari L. Ring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari L. Ring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari L. Ring more than expected).

Fields of papers citing papers by Kari L. Ring

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari L. Ring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari L. Ring. The network helps show where Kari L. Ring may publish in the future.

Co-authorship network of co-authors of Kari L. Ring

This figure shows the co-authorship network connecting the top 25 collaborators of Kari L. Ring. A scholar is included among the top collaborators of Kari L. Ring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kari L. Ring. Kari L. Ring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ring, Kari L., et al.. (2026). What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors. JAMA. 335(9). 749–749.
2.
Sharma, Sudarshan, Gabriel Lindahl, Lisa M. Landrum, et al.. (2025). Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up. International Journal of Gynecological Cancer. 35(2). 100243–100243.
3.
Jørgensen, Trine Lembrecht, Destin Black, David Cibula, et al.. (2024). Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. 42(16_suppl). 5607–5607. 1 indexed citations
4.
Previs, Rebecca A., Kyle C. Strickland, Zachary D. Wallen, et al.. (2024). Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology. 192. 102–110. 4 indexed citations
5.
6.
Banerjee, Susana, Carol Aghajanian, Els Van Nieuwenhuysen, et al.. (2024). LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. A13–A13. 1 indexed citations
7.
8.
Ring, Kari L., et al.. (2023). Factors affecting adherence to a high-risk surveillance protocol among patients with Li-Fraumeni syndrome. Hereditary Cancer in Clinical Practice. 21(1). 15–15. 2 indexed citations
9.
Ring, Kari L., Anne M. Mills, & Susan C. Modesitt. (2022). Endometrial Hyperplasia. Obstetrics and Gynecology. 140(6). 1061–1075. 56 indexed citations
10.
Ring, Kari L., et al.. (2021). MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status. International Journal of Gynecological Pathology. 41(1). 1–11. 4 indexed citations
11.
Mills, Anne M., et al.. (2020). β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas. International Journal of Gynecological Cancer. 30(7). 993–999. 8 indexed citations
12.
Modesitt, Susan C., et al.. (2019). Cases and evidence for panel testing in cancer genetics: Is site‐specific testing dead?. Journal of Genetic Counseling. 28(3). 700–707. 4 indexed citations
13.
Garcia, Christine, et al.. (2019). Genetic counseling referral for ovarian cancer patients: a call to action. Familial Cancer. 18(3). 303–309. 7 indexed citations
14.
Garcia, Christine & Kari L. Ring. (2018). The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. Current Treatment Options in Oncology. 19(12). 70–70. 15 indexed citations
15.
Ring, Kari L. & Susan C. Modesitt. (2018). Hereditary Cancers in Gynecology. Obstetrics and Gynecology Clinics of North America. 45(1). 155–173. 6 indexed citations
16.
17.
Ring, Kari L., Amanda Bruegl, Brian Allen, et al.. (2016). Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Modern Pathology. 29(11). 1381–1389. 86 indexed citations
18.
Slomovitz, Brian M., Yunyun Jiang, Melinda S. Yates, et al.. (2015). Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. Journal of Clinical Oncology. 33(8). 930–936. 201 indexed citations
19.
Conrad, Lesley B., Pedro T. Ramírez, William M. Burke, et al.. (2015). Role of Minimally Invasive Surgery in Gynecologic Oncology. International Journal of Gynecological Cancer. 25(6). 1121–1127. 99 indexed citations
20.
Ring, Kari L., et al.. (2013). Women 50 Years Or Younger With Endometrial Cancer: The Argument for Universal Mismatch Repair Screening and Potential for Targeted Therapeutics. International Journal of Gynecological Cancer. 23(5). 853–860. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bojana Djordjevic Breakdown of academic impact, for papers by Mervi Aavikko Breakdown of academic impact, for papers by David T. Bollag Breakdown of academic impact, for papers by Yaser Hussein Breakdown of academic impact, for papers by M.L. Carcangiu Breakdown of academic impact, for papers by Peter Lim Breakdown of academic impact, for papers by Barbara M. Buttin Breakdown of academic impact, for papers by Michael K. Cheung Breakdown of academic impact, for papers by Antonio De Leo Breakdown of academic impact, for papers by Vincent Castonguay
Rankless by CCL
2026